AM-Pharma Holding BV Announces Positive Phase I Data On recAP, For Acute Kidney Injury
3/26/2014 9:47:42 AM
BUNNIK, Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.
Help employers find you! Check out all the jobs and post your resume.
comments powered by